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1 Supplementary	  methods	  
1.1 Mathematical	  models	  
This	  section	  gives	  a	  brief	  summary	  of	  the	  features	  of	  the	  twelve	  epidemiological	  models	  included	  in	  
this	  analysis.	  Other	  than	  changes	  in	  ART	  eligibility	  and	  uptake,	  model	  projections	  do	  not	  include	  
other	  prevention	  efforts	  or	  changes	  in	  risk	  behaviour	  in	  future	  projections.	  Model	  projections	  of	  
population	  size,	  HIV	  prevalence,	  HIV	  incidence,	  and	  numbers	  on	  ART	  for	  the	  baseline	  epidemic	  
calibration	  are	  presented	  in	  section	  2.1.	  
1.1.1 Generalised	  epidemic	  settings	  
In	  the	  generalised	  epidemic	  settings,	  all	  models	  represented	  the	  entire	  adult	  population,	  aged	  15	  
years	  and	  older.	  For	  South	  Africa	  and	  Zambia,	  all	  models	  were	  calibrated	  to	  match	  the	  same	  
estimates	  for	  the	  size	  of	  the	  adult	  (aged	  15+	  years)	  population,	  HIV	  prevalence	  among	  15–49	  year	  
olds,	  and	  the	  number	  adults	  (aged	  15+	  years)	  on	  ART	  in	  mid-­‐2011	  in	  Table	  S1:	  
Table	  S1:	  Generalised	  epidemic	  calibration	  estimates1	  
	  
South	  Africa	   Zambia	  
Age	  15+	  population	  size,	  mid-­‐2011:	  	   35,015,633	   7,010,595	  
Age	  15–49	  HIV	  prevalence,	  mid-­‐2011:	   17.3%	   12.5%	  
Age	  15+	  number	  on	  ART,	  mid-­‐2011:	   1,416,100	   352,258	  
	  
Seven	  models	  (Goals,	  STDSIM,	  EMOD,	  BBH,	  PopART,	  Synthesis,	  Menzies)	  simulate	  the	  national	  HIV	  
epidemic	  in	  South	  Africa,	  and	  four	  simulate	  the	  national	  HIV	  epidemic	  in	  Zambia	  (Goals,	  EMOD,	  
Macha,	  PopART),	  with	  three	  (Goals,	  EMOD,	  PopART)	  separately	  calibrated	  to	  both	  settings.	  Goals,	  
BBH,	  PopART,	  Menzies,	  and	  Macha	  are	  deterministic	  compartmental	  models.	  STDSIM,	  EMOD,	  and	  
Synthesis	  are	  individual-­‐based	  microsimulation	  models.	  All	  models	  simulate	  HIV	  transmission	  
between	  two	  sexes	  except	  Menzies,	  which	  does	  not	  explicitly	  distinguish	  sexes.	  Goals,	  STDSIM,	  
EMOD,	  and	  Synthesis	  include	  age	  structure	  and	  age-­‐specific	  natural	  mortality	  rates,	  and	  Goals,	  
EMOD,	  and	  Synthesis	  incorporate	  more	  rapid	  HIV	  progression	  for	  older	  adults.	  BBH	  and	  Menzies	  
assume	  that	  sexual	  mixing	  and	  the	  risk	  of	  HIV	  infection	  are	  homogenous	  in	  the	  general	  population,	  
while	  the	  remaining	  models	  incorporate	  heterogeneity	  in	  sexual	  risk	  among	  the	  general	  population	  
in	  different	  ways.	  	  
In	  addition	  to	  heterogeneity	  in	  sexual	  mixing	  in	  the	  general	  population,	  four	  of	  the	  generalised	  
epidemic	  models	  (Goals,	  STDSIM,	  EMOD,	  BBH)	  include	  some	  key	  populations.	  Goals,	  STDSIM,	  and	  
BBH	  explicitly	  model	  HIV	  transmission	  among	  FSW.	  Goals	  and	  BBH	  simulate	  HIV	  transmission	  among	  
men	  who	  have	  sex	  with	  men	  (MSM),	  and	  BBH	  allows	  transmission	  between	  MSM	  and	  heterosexual	  
partners	  of	  MSM.	  	  
Goals,	  STDSIM,	  EMOD,	  BBH,	  and	  PopART	  model	  HIV	  progression	  and	  transmission	  as	  discrete	  stages.	  
For	  Goals,	  BBH	  and	  PopART	  these	  stages	  relate	  to	  CD4	  >500,	  CD4	  350–500,	  CD4	  200–350,	  and	  CD4	  
≤200	  cells/µL,	  while	  CD4	  count	  declines	  continuously	  after	  seroconversion	  and	  infectiousness	  is	  
represented	  as	  discrete	  stages	  related	  to	  stage	  of	  infection.	  Synthesis	  jointly	  and	  continuously	  
models	  CD4	  cell	  count	  decline,	  viral	  load,	  and	  the	  risk	  of	  morbidities,	  allowing	  these	  models	  to	  
consider	  eligibility	  for	  those	  with	  CD4	  ≤500	  cells/µL.	  HIV	  infectiousness	  increases	  as	  the	  CD4	  cell	  
count/category	  declines	  and	  each	  also	  incorporates	  a	  short	  period	  of	  high	  infectiousness	  
immediately	  after	  becoming	  infected.	  Menzies	  models	  HIV	  progression	  in	  stages	  of	  CD4	  >350,	  CD4	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200–350,	  and	  CD4	  ≤200	  cells/µL.	  Goals,	  PopART,	  and	  Menzies	  model	  the	  effect	  of	  HIV	  infection	  and	  
ART	  on	  progression	  to	  active	  tuberculosis	  (TB)	  disease	  and	  TB	  transmission.	  
1.1.2 Concentrated	  epidemic	  settings	  
Three	  models–Pruddell,	  Mishra,	  and	  IDU-­‐Manipur–represent	  different	  regions	  and	  epidemic	  types	  in	  
India.	  Mishra	  represents	  the	  entire	  adult	  (age	  >15	  years)	  population	  of	  Belgaum,	  India,	  where	  the	  
HIV	  epidemic	  is	  primarily	  driven	  sex	  work,	  and	  in	  which	  a	  successful	  targeted	  intervention	  
programme	  among	  FSW	  initially	  implemented	  through	  the	  Avahan	  intervention	  programme	  has	  
increased	  condom	  usage	  and	  access	  to	  ART	  among	  FSW,	  and	  thereby	  substantially	  reduced	  HIV	  
incidence	  over	  the	  past	  decade.2,3	  Mishra	  stratifies	  the	  population	  into	  high	  and	  low	  volume	  FSW,	  
former	  FSW,	  male	  clients	  of	  FSW,	  former	  male	  clients,	  and	  the	  remainder	  of	  the	  general	  population.	  
Mishra	  contributes	  two	  model	  simulations:	  one	  which	  projects	  HIV	  incidence	  including	  the	  
successful	  effects	  of	  the	  condom-­‐based	  prevention	  programme	  over	  the	  past	  decade,	  and	  a	  second	  
in	  which	  the	  epidemic	  is	  simulated	  assuming	  the	  increase	  in	  condom	  usage	  and	  ART	  access	  had	  not	  
occurred,	  resulting	  in	  higher	  HIV	  incidence,	  which	  we	  refer	  to	  as	  the	  ‘Mishra	  –	  no	  FSW	  intervention’	  
model.	  
Pruddell	  represents	  a	  subset	  of	  the	  adult	  population	  in	  Bangalore,	  India,	  where	  the	  epidemic	  is	  
primarily	  drive	  by	  FSW	  and	  MSM.	  The	  populations	  represented	  include	  current	  and	  former	  FSW,	  
male	  clients	  of	  FSW,	  and	  MSM,	  but	  does	  not	  include	  the	  general	  population,	  who	  may	  be	  sexual	  
partners	  of	  these	  populations.	  It	  simulates	  immediate	  ART	  and	  expanded	  access	  for	  current	  FSW	  and	  
MSM,	  and	  both	  of	  these	  groups	  simultaneously.	  	  
IDU-­‐Manipur	  represents	  a	  subset	  of	  the	  adult	  population	  in	  Churachandpur	  district	  in	  Manipur	  state,	  
where	  the	  epidemic	  is	  primarily	  driven	  by	  unsafe	  drug	  injecting.	  The	  persons	  represented	  include	  
high-­‐activity,	  low-­‐activity,	  and	  former	  PWID	  in	  Manipur,	  and	  heterosexual	  sexual	  partners	  of	  current	  
and	  former	  PWID.	  IDU-­‐Manipur	  also	  models	  hepatitis	  C	  virus	  (HCV)	  transmission	  through	  unsafe	  
injecting	  and	  HCV-­‐related	  liver	  disease	  progression.	  The	  model	  simulates	  the	  impact	  of	  immediate	  
ART	  and	  expanded	  access	  to	  current	  PWID	  and	  both	  current	  and	  former	  PWID.	  
None	  of	  the	  models	  for	  India	  simulate	  an	  ART	  eligibility	  threshold	  of	  CD4	  ≤500	  cells/µL,	  only	  
immediate	  eligibility	  for	  key	  populations	  compared	  to	  current	  eligibility	  guidelines.	  
In	  Vietnam,	  the	  Prevtool	  model	  represents	  the	  entire	  aged	  15–49	  population	  of	  Vietnam,	  
categorised	  into	  eight	  distinct	  groups:	  direct	  and	  indirect	  FSW,	  male	  clients	  of	  FSW,	  MSM,	  male	  and	  
female	  PWID,	  and	  the	  remaining	  males	  and	  females	  who	  are	  not	  members	  of	  these	  populations.	  The	  
model	  simulates	  immediate	  ART	  eligibility	  with	  status	  quo	  and	  prioritised	  expanded	  access	  for	  each	  
of	  FSW,	  MSM,	  and	  PWID,	  and	  immediate	  eligibility	  and	  expanded	  access	  for	  all	  three	  of	  these	  groups	  
simultaneously.	  It	  also	  simulates	  ART	  eligibility	  for	  CD4	  ≤500	  cells/µL	  for	  all	  adults,	  with	  prioritised	  
expanded	  access	  for	  these	  three	  groups.	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1.1.3 Model	  assumptions	  about	  ART	  
	  
HIV	  infectiousness	  
Table	  S2	  summarises	  the	  assumptions	  made	  by	  each	  model	  about	  the	  infectiousness	  of	  a	  typical	  HIV-­‐
positive	  person	  during	  each	  CD4	  cell	  count	  stage	  for	  persons	  on	  ART	  and	  not	  on	  ART,	  relative	  to	  the	  
infectiousness	  of	  an	  untreated	  person	  with	  CD4	  350–500	  cells/µL.	  For	  some	  models	  (STDSIM,	  EMOD,	  
Synthesis)	  CD4	  count	  is	  not	  directly	  related	  to	  infectiousness;	  values	  in	  the	  table	  represent	  derived	  
approximate	  values	  for	  relative	  infectiousness	  for	  persons	  in	  each	  CD4	  category.	  
Table	  S2:	  HIV	  infectiousness	  relative	  to	  untreated	  person	  with	  CD4	  350–500	  cells/µL	  
	   Not	  on	  ART	   On	  ART	  
Model	   Primary	  
Infection	  









Goals	   15.9	   1.0	   (reference)	   1.0	   4.8	   0.08	   0.08	   0.08	   0.08	  
STDSIM	   8.6	   1.0	   (reference)	   1.7	   2.7	   0.10	   0.10	   0.30	   0.75	  
EMOD	   26.7	   1.0	   (reference)	   1.0	   7.3	   0.08	   0.08	   0.08	   0.08	  
BBH	   9.0	   1.0	   (reference)	   1.0	   7.5	   0.04	   0.04	   0.04	   0.04	  
PopART	   26.0	   1.0	   (reference)	   1.0	   2.3	   0.10	   0.10	   0.10	   0.23	  
Synthesisa	   5.9	   0.9	   (reference)	   1.2	   1.4	   0.02	   0.05	   0.13	   0.33	  
Menzies	   N/A	   1.0	   (reference)	   7.3	   7.3	   0.04	   0.04	   0.29	   0.29	  
Macha	   27.0	   1.0	   (reference)	   1.0	   3.5	   0.03	   0.03	   0.03	   0.03	  
Pruddell	   18.5	   1.0	   (reference)	   1.0	   3.4	   0.05	   0.05	   0.05	   0.05	  
Mishra	   5.0	   1.0	   (reference)	   1.4	   5.0	   0.04	   0.04	   0.04	   0.04	  
IDU-­‐
Manipur	  
25.0	   1.0	   (reference)	   1.0	   7.6	   0.10	   0.10	   0.10	   0.10	  
Prevtool	   1.6	   1.6	   (reference)	   1.0	   3.8	   0.04	   0.04	   0.04	   0.04	  
a	  For	  the	  Synthesis	  model,	  HIV	  infectiousness	  is	  a	  function	  of	  individual	  HIV	  viral	  load,	  thus	  the	  values	  in	  the	  table	  reflect	  
the	  viral	  load	  distribution	  in	  the	  ART	  /	  CD4	  category.	  The	  rates	  per	  partnership	  per	  three	  month	  period	  are	  0.0001	  (VL	  
<500),	  0.01	  (VL	  500–5,000),	  0.03	  (VL	  5,000–50,000),	  0.06	  (VL	  50,000–500,000),	  0.1	  (VL	  >500,000).	  Viral	  load	  for	  untreated	  
individuals	  varies	  and	  increases	  as	  HIV	  infection	  progresses.	  For	  persons	  on	  ART,	  around	  90%	  are	  virally	  suppressed,	  
conferring	  a	  transmission	  rate	  of	  0.0001	  per	  3	  month	  period.	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Effect	  of	  ART	  on	  mortality/survival	  
Table	  S3	  summarises	  models’	  assumptions	  about	  the	  therapeutic	  benefits	  of	  ART	  for	  HIV-­‐positive	  
persons	  with	  different	  cell	  counts.	  
Table	  S3:	  Model	  assumptions	  about	  the	  therapeutic	  benefits	  of	  ART	  
Model	   Summary	  of	  therapeutic	  effects	  of	  ART	  
Goals	   The	  effect	  of	  ART	  on	  mortality	  varies	  by	  age,	  sex,	  CD4	  count	  at	  ART	  initiation,	  and	  duration	  on	  ART	  (<	  6	  mos,	  
6-­‐12	  mos,	  >	  12	  mos).	  ART	  has	  no	  effect	  on	  mortality	  for	  persons	  with	  CD4	  >500	  cells/µL.	  For	  persons	  with	  CD4	  
350-­‐500	  cells/µL,	  ART	  has	  no	  effect	  on	  mortality	  rates	  in	  the	  first	  year,	  and	  reduces	  mortality	  by	  around	  25%	  
thereafter.	  For	  persons	  with	  CD4	  200-­‐350	  cells/µL,	  ART	  reduces	  mortality	  by	  around	  55–85%	  after	  one	  year.	  
For	  persons	  with	  CD4	  ≤200	  cells/µL,	  ART	  reduces	  the	  mortality	  rate	  by	  45–80%	  in	  the	  first	  year,	  and	  by	  over	  
90%	  thereafter.	  Full	  details	  are	  available	  from	  the	  Spectrum	  model:	  
http://www.futuresinstitute.org/spectrum.aspx	  
STDSIM	   Untreated	  HIV-­‐positive	  persons	  progress	  through	  six	  symptom-­‐based	  stages:	  acute	  infection,	  two	  
asymptomatic	  stages,	  2	  symptomatic	  stages,	  and	  AIDS.	  Persons	  on	  ART	  progress	  through	  the	  same	  stages	  as	  
uninfected	  persons,	  at	  a	  4	  times	  slower	  rate	  after	  initiating	  treatment.	  
EMOD	   HIV-­‐positive	  persons	  proceed	  through	  three	  infectious	  stages	  (acute,	  asymptomatic,	  and	  AIDS),	  and	  CD4	  
count	  declines	  linearly	  until	  death.	  Survival	  after	  ART	  initiation	  depends	  on	  CD4	  count	  category	  (25–49,	  50–
99,	  100–199,	  200+	  cells/µL),	  age,	  sex,	  and	  presence	  of	  WHO	  Stage	  III/IV	  clinical	  disease.	  There	  is	  no	  additional	  
survival	  benefit	  for	  persons	  initiating	  CD4	  >350	  cells/µL	  compared	  to	  persons	  with	  CD4	  200-­‐350	  cells/µL.	  Full	  
details	  are	  available:	  http://arxiv.org/pdf/1206.3720.pdf	  
BBH	   Untreated	  HIV-­‐positive	  persons	  experience	  mortality	  rates	  of	  0.049	  per	  year	  (CD4	  >350	  cells/µL),	  0.077	  per	  
year	  (CD4	  200–350	  cells/µL),	  and	  0.237	  per	  year	  (CD4	  ≤200	  cells/µL).	  The	  mortality	  rate	  is	  reduced	  to	  0.027	  
per	  year	  for	  all	  persons	  on	  ART.	  	  
PopART	   Untreated	  HIV-­‐positive	  persons	  proceed	  through	  primary	  infection	  followed	  by	  four	  CD4	  cell	  count	  stages	  
(CD4	  >500,	  350–500,	  200–350,	  ≤200).	  Persons	  on	  ART	  progress	  through	  the	  same	  stages	  as	  uninfected	  
persons,	  at	  a	  2	  times	  slower	  rate	  after	  initiating	  treatment.	  
Synthesis	   Risk	  of	  mortality	  depends	  on	  CD4	  cell	  count,	  viral	  load,	  age,	  and	  being	  on	  ART.	  Persons	  on	  ART	  experience	  a	  
20%	  reduction	  in	  mortality	  compared	  to	  similar	  persons	  not	  on	  ART,	  plus	  additional	  reductions	  
commensurate	  with	  the	  suppression	  of	  viral	  load.	  Toxicities	  related	  to	  specific	  antiretroviral	  drugs	  effect	  small	  
additional	  risks	  of	  mortality	  (neophrotoxicity	  associated	  with	  tenofovir,	  pancreatitis	  associated	  with	  
didanosine	  or	  stavudine,	  and	  lactic	  acidosis	  associated	  with	  didanosine,	  stavudine	  or	  zidovudine).	  Taken	  
together,	  there	  is	  a	  modest	  therapeutic	  benefit	  for	  ART	  initiation	  at	  CD4	  count	  of	  500	  cells/µL	  versus	  CD4	  
count	  of	  350	  cells/µL	  (36%	  died	  after	  20	  years	  vs.	  40%	  died	  after	  20	  years).	  
Menzies	   For	  persons	  with	  CD4	  >350	  cells/µL,	  ART	  reduces	  the	  HIV-­‐specific	  mortality	  rate	  from	  0.0083	  per	  year	  for	  
untreated	  persons	  to	  0.0080	  per	  year.	  For	  those	  with	  CD4	  200–350	  cells/µL,	  ART	  reduces	  the	  mortality	  rate	  
from	  0.030	  per	  year	  to	  0.025	  per	  year.	  For	  those	  with	  CD4	  ≤200	  cells/µL,	  ART	  reduces	  the	  mortality	  rate	  from	  
0.257	  per	  year	  to	  0.051	  per	  year.	  Additional	  mortality	  results	  from	  TB	  disease.	  TB	  disease	  incidence	  increases	  
for	  untreated	  persons	  at	  lower	  CD4	  cell	  counts,	  and	  ART	  reduces	  the	  incidence	  of	  TB	  disease.	  	  
Macha	   Untreated	  HIV-­‐positive	  persons	  with	  CD4	  >200	  cells/µL	  experience	  a	  mortality	  rate	  of	  0.098	  per	  year.	  After	  
initiating	  ART,	  mortality	  is	  reduced	  to	  0.068	  per	  year	  for	  the	  first	  3	  months,	  to	  0.051	  per	  year	  for	  three	  to	  six	  
months	  on	  ART,	  and	  0.041	  per	  year	  after	  six	  months	  on	  ART.	  Untreated	  persons	  with	  CD4	  ≤200	  cells/µL	  
experience	  mortality	  at	  a	  rate	  of	  0.63	  per	  year.	  After	  ART	  initiation,	  mortality	  is	  reduced	  to	  0.19	  per	  year,	  
0.063	  per	  year,	  and	  0.06	  per	  year	  for	  <3	  months,	  3–6	  months,	  and	  6+	  months	  on	  ART.	  
Pruddell	   Untreated	  HIV-­‐positive	  persons	  proceed	  through	  acute	  infection	  followed	  by	  three	  CD4	  count	  stages	  (CD4	  
>350,	  200–350,	  ≤200	  cells/µL).	  Persons	  on	  ART	  proceed	  through	  the	  stages	  at	  1/3	  the	  rate	  of	  untreated	  
persons.	  	  
Mishra	   For	  persons	  with	  CD4	  >350	  cells/µL,	  mortality	  is	  reduced	  from	  0.025	  per	  year	  for	  untreated	  persons	  to	  0.0032	  
per	  year	  for	  treated	  persons.	  For	  those	  with	  CD4	  200–350	  cells/µL,	  mortality	  is	  reduced	  from	  0.08	  per	  year	  to	  
0.01	  per	  year	  when	  treated.	  For	  those	  with	  CD4	  ≤200	  cells/µL,	  mortality	  is	  reduced	  from	  0.5	  per	  year	  to	  0.05	  
per	  year	  when	  treated.	  Full	  reductions	  in	  mortality	  are	  only	  realised	  after	  the	  first	  year;	  during	  the	  first	  year	  
on	  ART	  reductions	  in	  mortality	  are	  half	  that	  ultimately	  achieved.	  
IDU-­‐
Manipur	  
Untreated	  HIV-­‐positive	  persons	  proceed	  through	  acute	  infection	  followed	  by	  three	  CD4	  count	  stages	  (CD4	  
>350,	  200–350,	  ≤200	  cells/µL).	  Persons	  on	  ART	  proceed	  through	  the	  stages	  at	  1/3	  the	  rate	  of	  untreated	  
persons.	  
Prevtool	   HIV	  positive	  persons	  experience	  mortality	  rates	  depending	  on	  their	  CD4	  cell	  count:	  0.0005	  per	  year	  (CD4	  >500	  
cells/µL),	  0.00128	  per	  year	  (CD4	  350–500	  cells/µL),	  0.011	  per	  year	  (CD4	  200–350	  cells/µL),	  and	  0.5	  per	  year	  
(CD4	  <	  200	  per	  year).	  Persons	  on	  ART	  reconstitute	  their	  CD4	  cell	  count	  and	  increase	  to	  higher	  CD4	  count	  
categories,	  thereby	  reducing	  their	  mortality	  risk.	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Retention	  on	  ART	  and	  re-­‐initiation	  
Table	  S4	  summarises	  models’	  assumptions	  about	  the	  therapeutic	  benefits	  of	  ART	  for	  HIV-­‐positive	  
persons	  with	  different	  cell	  counts.	  In	  this	  study,	  models	  did	  not	  assume	  that	  persons	  initiating	  ART	  
with	  higher	  CD4	  cell	  counts	  have	  poorer	  adherence	  or	  retention.	  
Table	  S4:	  Model	  assumptions	  about	  retention	  on	  ART	  and	  re-­‐initiation	  on	  ART	  after	  dropping	  out	  
Model	   Summary	  of	  model	  assumptions	  about	  retention	  on	  ART	  
	  
Goals	   Model	  does	  not	  explicitly	  simulate	  dropout	  from	  ART	  
	  
STDSIM	   Persons	  on	  ART	  stop	  treatment	  at	  a	  rate	  of	  0.05	  per	  year.	  Persons	  who	  have	  dropped	  out	  from	  treatment	  
reinitiate	  treatment	  at	  half	  the	  rate	  of	  ART	  naïve	  persons.	  
EMOD	   Persons	  on	  ART	  stop	  treatment	  at	  a	  rate	  of	  0.1	  per	  year.	  Half	  of	  persons	  can	  re-­‐enter	  care	  and	  reinitiate	  ART	  
at	  the	  same	  rate	  as	  treatment	  naïve	  individuals.	  The	  other	  half	  can	  only	  re-­‐initiate	  when	  experiencing	  
symptoms,	  or	  when	  brought	  to	  care	  by	  an	  HIV-­‐positive	  partner	  undergoing	  pre-­‐ART	  monitoring	  (which	  occurs	  
at	  low-­‐levels	  in	  the	  baseline	  model	  calibration),	  or	  when	  attending	  antenatal	  care.	  
BBH	   Model	  does	  not	  explicitly	  simulate	  dropout	  from	  ART.	  
	  
PopART	   All	  persons	  on	  ART	  stop	  treatment	  at	  a	  dropout	  rate	  of	  0.05	  per	  year.	  Persons	  who	  have	  dropped	  out	  of	  
treatment	  reenter	  care	  and	  reinitiate	  treatment	  at	  the	  same	  rate	  as	  treatment	  naïve	  persons	  in	  the	  same	  CD4	  
category.	  
Synthesis	   Persons	  on	  ART	  experience	  an	  annual	  rate	  of	  interrupting	  ART	  of	  0.08	  for	  people	  without	  toxicity	  and	  optimal	  
adherence,	  up	  to	  0.32	  for	  people	  with	  toxicities	  and	  poor	  average	  adherence	  (below	  50%)	  .	  People	  who	  
interrupted	  ART	  experience	  a	  0.4	  rate	  per	  3	  months	  of	  being	  lost	  from	  care.	  Those	  who	  interrupted	  ART	  but	  
who	  are	  still	  in	  care	  experience	  0.4	  probability	  of	  restarting	  tretament	  while	  people	  lost	  from	  care	  experience	  
a	  rate	  of	  0.1	  per	  3	  months	  of	  returning	  to	  care.	  
Menzies	   Model	  does	  not	  explicitly	  simulate	  dropout	  from	  ART.	  
Macha	   Persons	  on	  ART	  stop	  treatment	  at	  a	  rate	  of	  0.05	  per	  year.	  Persons	  who	  have	  dropped	  out	  reinitiate	  ART	  at	  the	  
same	  rate	  as	  persons	  in	  pre-­‐ART	  care.	  
Pruddell	   Persons	  on	  ART	  stop	  treatment	  at	  a	  rate	  of	  0.064	  per	  year.	  Persons	  who	  have	  dropped	  out	  are	  eligibile	  to	  
reinitiate	  treatment	  after	  their	  CD4	  cell	  count	  falls	  below	  CD4	  ≤200	  cells/µL,	  with	  the	  rate	  depending	  on	  the	  
symptomatic	  stage:	  0.01	  per	  year	  for	  CD4	  ≤200	  and	  asymptomatic,	  0.03	  per	  year	  for	  symptomatic	  pre-­‐AIDS,	  
and	  0.08	  per	  year	  for	  those	  with	  AIDS.	  
Mishra	   Persons	  on	  ART	  discontinued	  treatment	  or	  experienced	  virological	  treatment	  failure	  at	  a	  rate	  of	  7%	  in	  the	  first	  
year	  on	  treatment,	  and	  1%	  per	  year	  thereafter.	  Persons	  who	  have	  dropped	  out	  from	  ART	  reinitiate	  ART	  based	  
on	  experience	  of	  clinical	  symptoms	  at	  the	  same	  rate	  as	  ART	  naïve	  persons.	  
IDU-­‐
Manipur	  
Persons	  on	  ART	  stop	  treatment	  at	  a	  rate	  of	  0.1	  per	  year.	  Persons	  who	  have	  dropped	  out	  from	  ART	  are	  not	  
eligible	  to	  re-­‐initiate	  treatment	  until	  they	  reach	  the	  AIDS	  stage.	  
Prevtool	   Persons	  on	  ART	  dropout	  or	  discontinue	  treatment	  due	  to	  treatment	  failure	  at	  a	  rate	  of	  0.05	  per	  year.	  Persons	  
who	  have	  dropped	  out	  from	  ART	  recommence	  ART	  at	  a	  rate	  of	  0.07	  per	  year.	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Adherence	  and	  resistance	  	  
Two	  models,	  Prevtool	  and	  Synthesis,	  explicitly	  model	  viraemia	  related	  to	  poor	  adherence	  and	  the	  
development	  of	  resistance	  (see	  Synthesis	  model	  for	  details4.	  This	  viraemia	  increases	  the	  risk	  of	  
clinical	  progression	  and	  mortality	  as	  well	  as	  the	  risk	  of	  resistance.	  Other	  models	  implicitly	  account	  
for	  incomplete	  viral	  suppression	  related	  to	  poor	  adherence	  or	  resistance	  by	  assuming	  a	  persistent	  
low	  risk	  of	  HIV	  transmission	  for	  persons	  on	  ART	  (Table	  S2).	  
	  
Behaviour	  change	  in	  response	  to	  ART	  
Models	  did	  not	  assume	  any	  changes	  in	  population-­‐level	  sexual	  risk	  behaviour	  in	  the	  general	  
population	  (e.g.	  ‘risk	  compensation’)	  in	  response	  to	  earlier	  ART	  eligibility	  or	  expanded	  ART	  access.	  	  
Two	  models	  (Synthesis	  and	  Macha)	  assumed	  modest	  reductions	  in	  sexual	  risk	  behaviour	  among	  HIV	  
positive	  persons	  after	  being	  diagnosed	  with	  HIV.	  The	  other	  models	  did	  not	  assume	  changes	  in	  sexual	  
behaviour	  upon	  receiving	  a	  positive	  HIV	  diagnosis.	  The	  Synthesis	  model	  assumes	  receiving	  a	  positive	  
HIV	  diagnosis	  reduces	  the	  probability	  of	  having	  condom-­‐less	  sex	  in	  the	  first	  6	  months	  after	  diagnosis	  
by	  13%	  with	  a	  primary	  partner	  and	  by	  17%	  with	  a	  casual	  partner.	  After	  the	  first	  six	  months,	  the	  
reduction	  is	  9%.	  The	  Macha	  model	  assumes	  that	  the	  contact	  rate	  for	  HIV-­‐positive	  persons	  is	  reduced	  
by	  18.6%	  after	  receiving	  an	  HIV	  diagnosis..	  	  
Two	  other	  models	  (STDSIM	  and	  Pruddell)	  assumed	  that	  HIV	  positive	  persons	  in	  advanced	  disease	  
stages	  have	  reduced	  sexual	  risk	  behaviour.	  The	  STDSIM	  model	  assumes	  a	  50%	  reduction	  in	  the	  
frequency	  of	  sexual	  contact	  within	  regular	  partnerships	  for	  persons	  in	  the	  AIDS	  stage,	  while	  Pruddell	  
assumes	  cessation	  of	  all	  new	  sexual	  contacts	  for	  persons	  with	  symptomatic	  AIDS.	  Sexual	  activity	  
returns	  to	  normal	  levels	  upon	  ART	  initiation.	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1.2 Outputs	  reported	  by	  epidemiological	  models	  
Epidemiological	  models	  reported	  standardised	  outputs	  for	  each	  ART	  eligibility	  and	  access	  strategy	  
that	  were	  used	  for	  calculation	  of	  the	  incremental	  costs	  and	  health	  benefits.	  All	  models	  reported	  the	  
following	  outputs	  for	  the	  population	  at	  the	  midpoint	  of	  each	  year	  from	  2014	  through	  2033:	  
• The	  total	  size	  of	  the	  adult	  (age	  15+)	  population.	  
• The	  total	  number	  of	  HIV-­‐	  adults.	  
• The	  number	  of	  HIV+	  adults	  not	  in	  pre-­‐ART	  care	  with	  CD4	  >350	  cells/µL.	  
• The	  number	  of	  HIV+	  adults	  not	  in	  pre-­‐ART	  care	  with	  CD4	  200–350	  cells/µL.	  
• The	  number	  of	  HIV+	  adults	  not	  in	  pre-­‐ART	  care	  with	  CD4	  ≤200	  cells/µL.	  
• The	  number	  of	  HIV+	  adults	  in	  pre-­‐ART	  care	  with	  CD4	  >350	  cells/µL.	  
• The	  number	  of	  HIV+	  adults	  in	  pre-­‐ART	  care	  with	  CD4	  200–350	  cells/µL.	  
• The	  number	  of	  HIV+	  adults	  in	  pre-­‐ART	  care	  with	  CD4	  ≤200	  cells/µL.	  
• The	  number	  of	  HIV+	  adults	  on	  ART	  
All	  models	  also	  reported	  the	  following	  outputs	  about	  the	  number	  of	  events	  occurring	  during	  the	  
calendar	  year	  (1	  January	  to	  31	  December)	  annually	  from	  2014	  through	  2033:	  
• The	  number	  of	  new	  adult	  HIV	  infections.	  
• The	  number	  of	  infected	  adults	  entering	  pre-­‐ART	  care.	  
• The	  number	  of	  HIV	  diagnostic	  tests	  conducted	  (except	  BBH,	  PopART,	  and	  IDU-­‐Manipur,	  see	  
section	  1.3.1(c)).	  
• The	  number	  of	  adults	  initiating	  ART	  from	  pre-­‐ART	  care.	  
• The	  number	  of	  adults	  initiating	  ART	  not	  from	  pre-­‐ART	  care.	  
• The	  number	  of	  adult	  deaths.	  
Midyear	  population	  sizes	  were	  used	  as	  an	  approximation	  for	  person-­‐years	  lived	  in	  each	  state	  for	  the	  
calculation	  of	  rates.	  Models	  which	  simulated	  specific	  populations	  (FSW,	  MSM,	  PWID)	  reported	  the	  
number	  of	  diagnostic	  tests	  and	  number	  of	  persons	  entering	  pre-­‐ART	  care	  within	  each	  of	  these	  
populations.	  
Models	  which	  simulated	  TB	  disease	  reported:	  
• The	  number	  of	  adults	  with	  TB	  disease	  at	  midyear.	  
• The	  number	  of	  TB	  cases	  treated	  during	  the	  calendar	  year.	  
The	  IDU-­‐Manipur	  model,	  which	  also	  included	  hepatitis	  C	  virus	  (HCV)	  transmission	  among	  PWID,	  
reported	  the	  number	  of	  adults	  infected	  with	  HCV	  stratified	  according	  to	  the	  following	  disease	  
stages:	  mild/moderate	  HCV,	  compensated	  cirrhosis,	  decompensated	  cirrhosis,	  and	  hepatic	  
carcinoma.	  The	  following	  disability	  weights	  were	  associated	  with	  these	  four	  stages:	  0.036,	  0.123,	  
0.194,	  0.484.5	  No	  additional	  health	  costs	  were	  associated	  with	  HCV	  infection	  due	  to	  the	  lack	  of	  
availability	  of	  HCV	  treatment	  in	  this	  setting.	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1.3 Estimation	  of	  incremental	  costs	  associated	  with	  ART	  policy	  changes	  
1.3.1 General	  approach	  
Costs	  were	  assessed	  incrementally,	  and	  any	  programme	  area	  (or	  similar	  category	  of	  resource	  
consumption)	  which	  was	  thought	  to	  be	  unaffected	  by	  the	  changes	  in	  ART	  policy	  examined	  in	  this	  
analysis	  were	  not	  included	  in	  the	  costing.	  The	  following	  broad	  categories	  were	  included	  in	  the	  cost	  
assessment:	  
(a) service	  delivery	  costs	  for	  individuals	  receiving	  ART,	  
(b) service	  delivery	  costs	  for	  individuals	  receiving	  pre-­‐ART	  care,	  
(c) service	  delivery	  costs	  required	  to	  identify	  and	  link	  HIV-­‐positive	  individuals	  to	  care,	  	  
(d) cost	  savings	  due	  to	  reduced	  healthcare	  utilisation	  in	  the	  routine	  health	  system,	  and	  
(e) costs	  of	  higher-­‐level	  programmatic	  support	  and	  supply-­‐chain	  management.	  
The	  general	  framework	  for	  calculating	  total	  costs	  for	  each	  of	  these	  areas	  was	  to	  (i)	  describe	  the	  
relevant	  units	  of	  service	  delivery,	  (ii)	  estimate	  the	  unit	  costs	  for	  delivering	  those	  services,	  (iii)	  
estimate	  the	  quantity	  of	  services	  provided,	  and	  (iv)	  combine	  these	  estimates	  to	  calculate	  total	  
service	  delivery	  costs.	  
ART	  costs	  
ART	  costs	  were	  subdivided	  into	  ARV	  costs	  and	  non-­‐ARV	  costs.	  In	  general	  the	  models	  in	  this	  analysis	  
did	  not	  model	  the	  receipt	  of	  individual	  regimens	  by	  patients,	  and	  therefore	  ARV	  costs	  were	  modeled	  
as	  an	  overall	  average.	  Under	  each	  strategy,	  the	  total	  costs	  of	  ARV	  drugs	  in	  a	  given	  year	  were	  
calculated	  by	  multiplying	  the	  number	  of	  person-­‐years	  of	  ART	  in	  that	  year	  (estimated	  as	  ART	  patient	  
volume	  at	  midyear)	  by	  the	  average	  annual	  cost	  of	  an	  ART	  regimen.	  Regimen	  distributions,	  including	  
both	  first-­‐	  and	  second-­‐line	  ARV	  regimens,	  were	  based	  on	  reported	  data	  for	  each	  country,	  thus	  
reflecting	  current	  prescribing	  practices.	  Prices	  for	  each	  regimen	  were	  calculated	  using	  average	  drug	  
prices	  obtained	  from	  the	  WHO	  Global	  Price	  Reporting	  System6.	  The	  average	  annual	  regimen	  cost	  
was	  calculated	  as	  the	  weighted	  average	  cost	  across	  all	  first-­‐	  and	  second-­‐line	  regimens.	  
Non-­‐ARV	  service	  delivery	  costs	  were	  subdivided	  into	  ART	  initiation	  costs	  and	  established	  patient	  
costs.	  Under	  each	  strategy,	  the	  ART	  initiation	  costs—accounting	  for	  the	  additional	  laboratory	  tests	  
and	  clinic	  visits	  incurred	  during	  a	  patient’s	  initial	  months	  on	  ART—were	  calculated	  by	  multiplying	  the	  
number	  of	  individuals	  initiating	  ART	  in	  a	  given	  year	  by	  the	  ART	  initiation	  unit	  cost,	  which	  was	  
obtained	  from	  an	  evidence	  synthesis	  of	  available	  costing	  data.	  For	  patients	  who	  were	  not	  in	  pre-­‐ART	  
care	  before	  ART	  initiation,	  ART	  initiation	  costs	  include	  an	  additional	  cost	  of	  an	  HIV	  diagnostic	  test	  
and	  CD4	  cell	  count	  measurement,	  which	  will	  have	  been	  accounted	  for	  in	  HIV	  testing	  &	  linkage	  costs	  
and	  pre-­‐ART	  care	  costs	  (see	  below)	  for	  those	  patients	  who	  initiate	  ART	  after	  being	  in	  pre-­‐ART	  care.	  
Establish	  patient	  costs—accounting	  for	  the	  regular	  clinical	  care	  and	  laboratory	  monitoring	  received	  
by	  ART	  patients,	  as	  well	  as	  all	  other	  site-­‐level	  activities	  required	  for	  the	  functioning	  of	  the	  ART	  
programme—were	  calculated	  by	  multiplying	  the	  number	  of	  person-­‐years	  of	  ART	  in	  that	  year	  
(estimated	  as	  ART	  patient	  volume	  at	  midyear)	  by	  the	  established	  ART	  patient	  unit	  cost,	  obtained	  
from	  an	  evidence	  synthesis	  of	  available	  costing	  data.	  Non-­‐ARV	  service	  delivery	  costs	  were	  calculated	  
as	  the	  sum	  of	  initiation	  and	  establish	  patient	  costs,	  and	  total	  ART	  costs	  calculated	  as	  the	  sum	  of	  ARV	  
and	  non-­‐ARV	  costs.	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Pre-­‐ART	  costs	  
Pre-­‐ART	  patients	  receive	  regular	  clinical	  and	  laboratory	  monitoring	  to	  assess	  their	  eligibility	  for	  ART	  
initiation,	  as	  well	  as	  prophylaxis	  and	  treatment	  of	  opportunistic	  infections,	  and	  other	  HIV	  care	  
services	  provided	  by	  the	  HIV	  treatment	  programme.	  Under	  each	  strategy,	  the	  total	  costs	  of	  pre-­‐ART	  
care	  in	  a	  given	  year	  were	  calculated	  by	  multiplying	  the	  number	  of	  person-­‐years	  of	  pre-­‐ART	  in	  that	  
year	  (estimated	  as	  pre-­‐ART	  patient	  volume	  at	  midyear)	  by	  the	  pre-­‐ART	  patient	  unit	  cost,	  obtained	  
from	  an	  evidence	  synthesis	  of	  available	  costing	  data.	  
HIV	  testing	  costs	  
The	  strategies	  in	  these	  analyses	  focused	  on	  various	  approaches	  for	  providing	  HIV	  treatment,	  and	  
some	  of	  these	  approaches	  (particularly	  the	  expanded	  access	  strategies)	  required	  a	  substantial	  
acceleration	  in	  the	  rate	  at	  which	  HIV-­‐positive	  individuals	  are	  identified	  for	  care	  and	  treatment.	  Most	  
models	  included	  mechanistic	  representations	  of	  the	  volume	  of	  HIV	  testing	  required	  to	  achieve	  the	  
levels	  of	  ART	  scale-­‐up	  specified	  for	  each	  healthcare	  access	  strategy.	  For	  those	  models	  which	  
reported	  testing	  volumes	  (Goals,	  STDSIM,	  EMOD,	  Synthesis,	  Menzies,	  Macha,	  Pruddell,	  Mishra,	  and	  
Prevtool),	  total	  testing	  costs	  for	  a	  given	  year	  were	  calculated	  by	  multiplying	  the	  total	  number	  of	  
individuals	  receiving	  an	  HIV	  test	  during	  the	  year	  by	  the	  VCT	  unit	  cost,	  which	  was	  obtained	  from	  an	  
evidence	  synthesis	  of	  available	  costing	  data.	  For	  models	  which	  did	  not	  have	  a	  mechanism	  for	  
estimating	  testing	  volume	  (BBH,	  PopART,	  IDU-­‐Manipur),	  we	  developed	  a	  simple	  function	  for	  
estimating	  testing	  costs	  based	  on	  (i)	  the	  rate	  at	  which	  HIV-­‐positive	  adults	  who	  were	  not	  in	  care	  
entered	  care	  in	  each	  year,	  (ii)	  a	  multiplier	  to	  account	  for	  loss-­‐to-­‐follow-­‐up	  between	  HIV	  testing	  and	  
HIV	  care,	  and	  (iii)	  the	  VCT	  unit	  cost.	  We	  estimated	  the	  rate	  of	  entering	  care	  as	  the	  number	  of	  people	  
initiating	  HIV	  care	  in	  a	  given	  year	  divided	  by	  the	  total	  HIV	  positive	  population	  not	  yet	  receiving	  pre-­‐
ART	  or	  ART	  at	  midyear.	  This	  rate	  is	  multiplied	  by	  the	  average	  number	  of	  diagnoses	  per	  person	  
entering	  care,	  taken	  to	  be	  1.7	  based	  on	  the	  results	  of	  a	  systematic	  review	  and	  meta-­‐analysis,7	  to	  
estimate	  the	  rate	  of	  HIV	  testing	  among	  persons	  living	  with	  HIV	  who	  are	  not	  in	  care.	  This	  testing	  rate	  
is	  converted	  to	  an	  annual	  probability	  of	  being	  tested	  for	  adults	  living	  with	  HIV.	  It	  was	  assumed	  that	  
HIV-­‐negative	  adults	  were	  0.65	  times	  as	  likely	  to	  be	  tested	  as	  infected	  adults,8,9	  and	  the	  annual	  
percentage	  of	  HIV-­‐negative	  adults	  testing	  was	  estimated	  as	  the	  testing	  percentage	  of	  infected	  adults	  
times	  this	  factor.	  The	  total	  annual	  testing	  volume	  was	  obtained	  by	  multiplying	  the	  number	  of	  adults	  
living	  with	  HIV	  who	  are	  not	  on	  ART	  or	  in	  pre-­‐ART	  care	  and	  the	  number	  of	  HIV-­‐negative	  adults	  by	  
their	  annual	  testing	  percentages.	  Total	  testing	  costs	  for	  a	  given	  year	  were	  calculated	  by	  multiplying	  
the	  testing	  volume	  for	  that	  year	  by	  the	  VCT	  unit	  cost.	  For	  models	  to	  which	  this	  was	  applied	  that	  
included	  key	  populations	  (BBH:	  FSW,	  MSM;	  IDU-­‐Manipur:	  PWID),	  the	  rate	  of	  testing	  was	  calculated	  
separately	  for	  these	  populations	  and	  for	  the	  general	  population	  who	  were	  not	  part	  of	  these	  
populations.	  For	  key	  populations	  (FSW,	  MSM,	  PWID),	  an	  additional	  component	  was	  added	  to	  the	  
unit	  cost	  to	  represent	  the	  additional	  costs	  required	  for	  outreach	  to	  these	  groups.	  
Cost	  savings	  in	  the	  general	  health	  system	  
The	  cost	  categories	  described	  above	  capture	  the	  costs	  incurred	  within	  an	  HIV	  programme	  for	  
identification,	  care	  and	  treatment	  of	  HIV-­‐positive	  individuals.	  Even	  if	  not	  identified	  and	  linked	  to	  an	  
HIV	  treatment	  programme,	  an	  individual	  with	  HIV	  will	  exhibit	  greater	  health	  care	  utilisation,	  the	  
costs	  of	  which	  will	  be	  eliminated	  when	  the	  individual	  begins	  receiving	  their	  care	  from	  an	  HIV	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treatment	  programme.	  These	  other	  care	  costs	  were	  subdivided	  into	  an	  annual	  healthcare	  utilisation	  
cost	  and	  end-­‐of-­‐life	  care	  costs.	  	  
Annual	  healthcare	  utilisation	  costs	  were	  estimated	  for	  the	  individuals	  with	  untreated	  HIV	  (CD4	  cell	  
count	  categories	  >350	  cells/µL	  ,	  200–350	  cells/µL	  and	  ≤200	  cells/µL).	  Annual	  healthcare	  utilisation	  
costs	  for	  an	  individual	  with	  untreated,	  HIV	  were	  estimated	  from	  annualised	  frequencies	  of	  
outpatient	  visits	  and	  inpatient	  days10	  adjusted	  for	  the	  different	  rates	  of	  opportunistic	  infection	  
observed	  with	  each	  CD4	  category11–13	  multiplied	  by	  estimates	  of	  the	  unit	  costs	  of	  outpatient	  visits	  
and	  inpatient	  days	  obtained	  from	  WHO	  CHOICE14.	  Under	  each	  strategy,	  the	  total	  healthcare	  
utilisation	  costs	  in	  a	  given	  year	  were	  calculated	  by	  multiplying	  the	  number	  of	  person-­‐years	  of	  
untreated	  HIV	  with	  CD4	  >350	  cells/µL,	  CD4	  200–350	  cells/µL,	  and	  CD4	  ≤200	  cells/µL	  (estimated	  as	  
the	  total	  number	  of	  individuals	  in	  those	  categories	  at	  midyear)	  by	  the	  annualised	  cost	  for	  each	  of	  
these	  categories.	  For	  the	  subset	  of	  models	  which	  modelled	  changes	  in	  TB	  service	  utilisation	  as	  a	  
function	  of	  HIV	  policy	  (Goals,	  EMOD,	  Menzies),	  these	  changes	  in	  TB	  control	  cost	  were	  estimated	  as	  
the	  total	  number	  of	  individuals	  receiving	  TB	  treatment	  in	  a	  given	  year	  multiplied	  by	  the	  unit	  cost	  of	  a	  
course	  of	  TB	  treatment	  obtained	  from	  an	  evidence	  synthesis	  of	  available	  costing	  data.	  
End-­‐of-­‐life	  care	  costs	  were	  assumed	  to	  be	  the	  same	  for	  all	  individuals.	  For	  each	  strategy,	  total	  end-­‐
of-­‐life	  care	  costs	  were	  estimated	  as	  the	  number	  of	  inpatient	  days	  incurred	  by	  HIV	  positive	  individuals	  
in	  the	  6	  months	  preceding	  death,10	  multiplied	  by	  the	  unit	  cost	  per	  inpatient	  day	  obtained	  from	  
WHO-­‐CHOICE14,	  multiplied	  by	  the	  total	  number	  of	  individuals	  dying	  in	  a	  given	  year.	  	  
Programmatic	  support	  and	  supply-­‐chain	  management	  
Programme	  costs—the	  costs	  of	  management,	  administration,	  training,	  M&E	  and	  other	  activities	  
undertaken	  to	  support	  direct	  service	  provision—are	  a	  poorly	  understood	  component	  of	  HIV	  
treatment	  programmes,	  but	  can	  represent	  a	  non-­‐trivial	  fraction	  of	  total	  costs.	  Estimates	  of	  
programme	  costs	  for	  PMTCT	  services	  suggest	  that	  these	  costs	  can	  represent	  4–18%	  of	  total	  
programme	  costs,	  and	  from	  34–97%	  of	  total	  costs	  for	  HIV	  education	  services.15	  For	  this	  the	  purposes	  
of	  this	  costing	  programme	  costs	  were	  subdivided	  into	  supply-­‐chain	  management	  costs	  general	  
programmatic	  support.	  Supply	  chain	  management	  (SCM)	  costs	  were	  estimated	  as	  a	  fixed	  mark-­‐up	  on	  
top	  of	  the	  total	  costs	  of	  ARVs,	  covering	  insurance,	  transportation,	  storage	  and	  distribution	  of	  ARV	  
drugs	  as	  well	  as	  other	  SCM	  planning	  and	  management	  activities.	  This	  mark-­‐up	  was	  estimated	  at	  20%	  
based	  on	  consultation	  with	  ARV	  supply	  chain	  experts	  (Elliot	  Raizes	  (US	  CDC),	  Joel	  Kuritsky	  (USAID),	  
personal	  communication	  December	  14th	  2012).	  General	  programmatic	  support	  was	  estimated	  as	  a	  
50%	  mark-­‐up	  on	  top	  of	  direct	  non-­‐ARV	  service	  provision	  costs	  (i.e.	  representing	  33%	  of	  the	  total	  
non-­‐ARV	  service	  provision	  cost)	  based	  on	  input	  of	  costing	  and	  programmatic	  experts	  attending	  the	  
model	  harmonisation	  meeting	  held	  for	  this	  project	  in	  London,	  November	  2012.	  
1.3.2 Evidence	  synthesis	  for	  unit	  cost	  estimates	  
A	  number	  of	  the	  unit	  costs	  used	  for	  this	  analysis	  were	  derived	  from	  an	  evidence	  synthesis	  of	  
available	  costing	  data.	  For	  some	  countries,	  empirical	  costing	  data	  were	  not	  available	  for	  all	  of	  the	  
different	  unit	  costs	  needed	  for	  the	  analysis.	  In	  other	  countries,	  multiple	  estimates	  were	  available	  for	  
a	  given	  unit	  cost.	  This	  evidence	  synthesis	  adopted	  a	  Bayesian	  meta-­‐analysis	  approach16,17	  to	  pool	  
data	  within	  data	  rich	  settings,	  and	  to	  provide	  reasonable	  unit	  cost	  estimates	  for	  settings	  were	  
empirical	  data	  were	  not	  available.	  Empirical	  data	  were	  gathered	  from	  costing	  studies	  conducted	  in	  
the	  countries	  included	  in	  this	  analysis	  and	  similar	  settings,	  from	  the	  published	  literature,	  summary	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reports,	  and	  from	  unpublished	  estimates	  from	  recently	  completed	  studies.	  Estimates	  were	  inflated	  
to	  2012	  price	  levels	  using	  the	  GDP	  deflator	  in	  each	  country18	  and	  converted	  to	  US	  dollars	  at	  market	  
exchange	  rates.	  These	  adjusted	  estimates	  were	  combined	  in	  a	  generalised	  linear	  mixed	  effects	  
regression	  to	  control	  for	  differences	  in	  price	  level	  between	  countries	  and	  for	  historical	  time	  trends	  in	  
unit	  cost	  associated	  with	  economies	  of	  scale	  and	  programme	  maturation.	  Weakly	  informative	  priors	  
were	  used	  for	  model	  parameters,	  and	  the	  error	  distribution	  for	  logged	  costs	  was	  based	  a	  t-­‐
distribution	  to	  allow	  for	  outliers	  in	  the	  empirical	  cost	  estimates.	  This	  analysis	  was	  used	  to	  estimate	  
unit	  cost	  for	  each	  service	  in	  each	  country.	  Point	  estimates	  and	  credible	  intervals	  for	  all	  unit	  costs,	  
including	  those	  derived	  from	  the	  evidence	  synthesis,	  are	  shown	  in	  Table	  S5.	  A	  list	  of	  sources	  used	  in	  
the	  evidence	  synthesis	  is	  given	  in	  Table	  S6.	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Table	  S5:	  Posterior	  mean	  (95%	  credible	  interval)	  unit	  cost	  estimates	  (2012	  US	  dollars)	  
	  
South	  Africa	   Zambia	   India	   Vietnam	  
ART:	  ARV	  drug	  costs	   143	  (107	  -­‐	  179)	   141	  (106	  -­‐	  176)	   91	  (68	  -­‐	  114)	   105	  (99	  -­‐	  165)	  
ART:	  non-­‐ARV	  costs,	  initiation	  
(previously	  receiving	  pre-­‐ART)	  
95	  (68	  -­‐	  125)	   49	  (33	  -­‐	  65)	   29(19	  -­‐	  41)	   45	  (35	  -­‐	  56)	  
ART:	  non-­‐ARV	  costs,	  initiation	  
(previously	  untreated	  patient)	  
126	  (88	  -­‐	  175)	   65	  (42	  -­‐	  92)	   38	  (25	  -­‐	  57)	   59	  (45	  -­‐	  79)	  
ART:	  non-­‐ARV	  costs,	  established	  
patient	  
422	  (317	  -­‐	  494)	   217	  (138	  -­‐	  276)	   128	  (86	  -­‐	  171)	   198	  (161	  -­‐	  245)	  
Pre-­‐ART:	  CD4	  >	  350	   205	  (115	  -­‐	  281)	   127	  (58	  -­‐	  182)	   73	  (36	  -­‐	  112)	   145	  (110	  -­‐	  186)	  
Pre-­‐ART:	  CD4	  200	  -­‐	  350	   238	  (142	  -­‐	  319)	   139	  (69	  -­‐	  196)	   81	  (43	  -­‐	  121)	   150	  (114	  -­‐	  192)	  
Pre-­‐ART:	  CD4	  <	  200	   359	  (267	  -­‐	  434)	   185	  (116	  -­‐	  239)	   109	  (72	  -­‐	  148)	   169	  (134	  -­‐	  210)	  
HIV	  testing	   20	  (14	  -­‐	  26)	   10	  (6	  -­‐	  14)	   6	  (4	  -­‐	  9)	   9	  (7	  -­‐	  12)	  
Cost	  of	  identifying	  high	  risk	  
populations	  (FSW,	  MSM,	  PWID)	  
67	  (46	  -­‐	  93)	   34	  (21	  -­‐	  49)	   20	  (14	  -­‐	  29)	   31	  (23	  -­‐	  41)	  
Healthcare	  utilisation	  cost	  for	  HIV	  
positive,	  untreated,	  CD4	  >	  350	  
13	  (6	  -­‐	  20)	   5	  (2	  -­‐	  8)	   3	  (1	  -­‐	  5)	   2	  (1	  -­‐	  3)	  
Healthcare	  utilisation	  cost	  for	  HIV	  
positive,	  untreated,	  CD4	  200	  -­‐	  350	  
46	  (33	  -­‐	  58)	   17	  (13	  -­‐	  22)	   11	  (8	  -­‐	  14)	   7	  (5	  -­‐	  9)	  
Healthcare	  utilisation	  cost	  for	  HIV	  
positive,	  untreated,	  CD4	  <	  200	  
167	  (158	  -­‐	  173)	   63	  (60	  -­‐	  65)	   39	  (37	  -­‐	  41)	   26	  (25	  -­‐	  27)	  
TB	  treatment	   364	  (253	  -­‐	  499)	   188	  (111	  -­‐	  273)	   110	  (66	  -­‐	  166)	   172	  (114	  -­‐	  245)	  
End-­‐of-­‐life	  care	   160	  (68	  -­‐	  248)	   50	  (21	  -­‐	  77)	   34	  (15	  -­‐	  53)	   32	  (13	  -­‐	  49)	  
Supply	  chain	  management	  (%,	  
multiplier	  on	  ARV	  costs)	  
20%	  
(15%	  -­‐	  25%)	  
20%	  
(15%	  -­‐	  25%)	  
20%	  
(15%	  -­‐	  25%)	  
20%	  
(15%	  -­‐	  25%)	  
Programmatic	  support	  (%,	  multiplier	  
on	  non-­‐ARV	  costs)	  
50%	  
(25%	  -­‐	  75%)	  
50%	  
(25%	  -­‐	  75%)	  
50%	  
(25%	  -­‐	  75%)	  
50%	  
(25%	  -­‐	  75%)	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Table	  S6:	  Sources	  used	  for	  evidence	  synthesis	  of	  unit	  costs	  
Data	  Source	   Countries	   Unit	  Costs	   Citation	  
Cleary	  2006	   South	  Africa	   Established	  ART	   10	  
Deghaye	  2006	   South	  Africa	   Established	  ART	   19	  
John	  2006	   India	   Established	  ART	   20	  
McConnel	  2006	   South	  Africa	   HIV	  testing	   21	  
Thielman	  2006	   Tanzania	   HIV	  testing	   22	  
Bassett	  2007	   South	  Africa	   HIV	  testing	   23	  
Fung	  2007	   India	   Outreach	  to	  high-­‐risk	  groups	   24	  
Harling	  2007	   South	  Africa	   Established	  ART	   25	  
Dandona	  2008	   India	   Outreach	  to	  high-­‐risk	  groups,	  HIV	  testing	   26	  
Dowdy	  2008	   South	  Africa,	  Brazil,	  Kenya	   TB	  treatment	   27	  
Hounton	  2008	   Benin	   Established	  ART	   28	  
Rosen	  2008	   South	  Africa	   Established	  ART	   29	  
Vella	  2008	   South	  Africa	   Established	  ART	   30	  
Aldridge	  2009	   Peru	   Outreach	  to	  high-­‐risk	  groups	   31	  
Bikilla	  2009	   Ethiopia,	  Uganda	   Established	  ART	   32	  
Dandona	  2009	   India	   Outreach	  to	  high-­‐risk	  groups	   33	  
Gupta	  2009	   India	   Established	  ART	   34	  
Martinson	  2009	   South	  Africa	   Pre-­‐ART,	  ART	  initiation,	  established	  ART	   35	  
Menzies	  2009	   Uganda	   HIV	  testing	   36	  
Negin	  2009	   Kenya	   HIV	  testing	   37	  
Bratt	  2010	   Zambia	   HIV	  testing,	  ART	  initiation	   38	  
Datiko	  2010	   Ethiopia	   TB	  treatment	   39	  
Grabbe	  2010	   Kenya	   HIV	  testing	   40	  
Long	  2010	   South	  Africa	   Established	  ART	   41	  
Steffen	  2010	   Brazil	   TB	  treatment	   42	  
Tumwesigye	  2010	   Uganda	   HIV	  testing	   43	  
CDC	  2011a	   Mozambique	   Pre-­‐ART,	  ART	  initiation,	  established	  ART	   44	  
CDC2011b	   Tanzania	   Pre-­‐ART,	  ART	  initiation,	  established	  ART	   45	  
Chandrashekar	  2011	   India	   Outreach	  to	  high-­‐risk	  groups	   46	  
Kahn	  2011	   Uganda,	  Kenya	   HIV	  testing	   47	  
Menzies	  2011	   Botswana,	  Ethiopia,	  Nigeria,	  
Uganda,	  Vietnam	  
Pre-­‐ART,	  ART	  initiation,	  established	  ART	   48	  
Prado	  2011	   Brazil	   TB	  treatment	   49	  
Rosen	  2011	   Ghana	   Established	  ART,	  Pre-­‐ART	   50	  
Samandari	  2011	   Botswana	   TB	  treatment	   51	  
Vassall	  2011	   South	  Africa,	  India,	  Uganda	   TB	  treatment	   52	  
Aliyu	  2012	   Nigeria	   HIV	  testing,	  established	  ART	   53	  
CDC	  2012	   Kenya	   Pre-­‐ART,	  ART	  initiation,	  established	  ART	   54	  
FHI	  2012	   Vietnam	   Outreach	  to	  high-­‐risk	  groups,	  HIV	  testing	   Unpublished	  data	  
Marseille	  2012	   Zambia	   Established	  ART	   55	  
Menzies	  2012	   South	  Africa	   TB	  treatment	   56	  
Meyer-­‐Rath	  2012	   South	  Africa	   TB	  treatment	   57	  
Minh	  2012	   Vietnam	   Outreach	  to	  high-­‐risk	  groups	   58	  
Nichols	  2012	   Zambia	   HIV	  testing	   59	  
Obure	  2012	   Kenya,	  Swaziland	   HIV	  testing	   60	  
Pho	  2012	   India	   TB	  treatment	   61	  
Tran	  2012a	   Vietnam	   Established	  ART	   62	  
Tran	  2012b	   Vietnam	   HIV	  testing,	  ART	  initiation	   63	  
Thuy	  2012	   Vietnam	   Pre-­‐ART,	  ART	  initiation,	  established	  ART	   64	  
CHAI	  2013	   Rwanda,	  Malawi,	  Ethiopia,	  
Zambia,	  South	  Africa	  
Pre-­‐ART,	  established	  ART	   65	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2 Supplementary	  results	  
2.1 Baseline	  model	  calibration	  
The	  following	  figures	  S1	  –	  S5	  illustrate	  the	  HIV	  epidemic	  projections	  for	  the	  baseline	  simulation	  
assuming	  continuation	  of	  ART	  eligibility	  for	  CD4	  ≤350	  cells/µL	  and	  status	  quo	  access	  to	  care.	  
	  
Figure	  S1:	  Total	  adult	  population	  size	  (in	  millions)	  for	  the	  baseline	  simulation,	  assuming	  eligibility	  for	  
CD4	  ≤350	  cells/µL	  and	  status	  quo	  access	  to	  care.	  
	  
Figure	  S2:	  Adult	  HIV	  prevalence	  for	  the	  baseline	  simulation,	  assuming	  eligibility	  for	  CD4	  ≤350	  
cells/µL	  and	  status	  quo	  access	  to	  care.	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Figure	  S3:	  Adult	  HIV	  incidence	  rate	  per	  100	  person-­‐years	  for	  the	  baseline	  simulation,	  assuming	  
eligibility	  for	  CD4	  ≤350	  cells/µL	  and	  status	  quo	  access	  to	  care.	  
	  
	  
Figure	  S4:	  The	  percentage	  of	  adults	  living	  with	  HIV	  who	  are	  on	  ART	  for	  the	  baseline	  simulation,	  
assuming	  eligibility	  for	  CD4	  ≤350	  cells/µL	  and	  status	  quo	  access	  to	  care.	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2.2 The	  accumulation	  of	  health	  benefits	  and	  costs	  over	  time	  
The	  following	  figures	  illustrate	  how	  the	  health	  benefits	  and	  costs	  of	  each	  strategy	  accumulate	  over	  
time.	  
	  
Figure	  S5:	  Annual	  adult	  mortality	  rate	  per	  100	  person-­‐years.	  Strategies	  represented	  are	  the	  same	  as	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Figure	  S6:	  The	  additional	  life-­‐years	  lived	  in	  each	  year	  (thousands,	  undiscounted)	  compared	  to	  
baseline	  strategy	  of	  eligibility	  for	  CD4	  ≤350	  cells/µL	  and	  status	  quo	  access	  to	  care.	  Strategies	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Figure	  S7:	  The	  incremental	  costs	  incurred	  in	  each	  year	  (millions	  US$,	  undiscounted)	  compared	  to	  
baseline	  strategy	  of	  eligibility	  for	  CD4	  ≤350	  cells/µL	  and	  status	  quo	  access	  to	  care.	  Strategies	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2.3 Incremental	  cost-­‐effectiveness	  ratios	  for	  varied	  time	  horizons	  and	  discount	  
rates	  
Table	  S7:	  Cost	  per	  DALY	  averted	  (2012	  US$)	  comparing	  select	  strategies	  in	  models	  for	  South	  Africa	  
	  	   	  	   5	  years	   10	  years	   20	  years	  
	  	   	  	   0%	  disc.	   3%	  disc.	   6%	  disc	   0%	  disc.	   3%	  disc.	   6%	  disc	   0%	  disc.	   3%	  disc.	   6%	  disc	  
CD4	  ≤500,	  status	  
quo	  vs.	  CD4	  ≤350,	  
status	  quo	  
Goals	   $2,073	   $2,140	   $2,208	   $665	   $735	   $811	   $221	   $273	   $336	  
STDSIM	   $4,708	   $4,791	   $4,873	   $2,468	   $2,620	   $2,776	   $748	   $918	   $1,117	  
EMOD	   $11,358	   $11,646	   $11,942	   $4,156	   $4,391	   $4,642	   $1,328	   $1,560	   $1,830	  
BBH	   $3,952	   $4,063	   $4,175	   $1,655	   $1,763	   $1,879	   $740	   $839	   $956	  
PopART	   $3,722	   $3,771	   $3,819	   $1,714	   $1,830	   $1,950	   $681	   $790	   $919	  
Synthesis	   $4,918	   $4,982	   $5,046	   $2,835	   $2,927	   $3,025	   $1,553	   $1,691	   $1,843	  
All	  HIV+,	  status	  
quo	  vs.	  CD4	  ≤350,	  
status	  quo	  
Goals	   $4,393	   $4,525	   $4,658	   $1,370	   $1,496	   $1,630	   $345	   $438	   $552	  
STDSIM	   $17,571	   $17,869	   $18,169	   $9,530	   $10,018	   $10,525	   $3,243	   $3,790	   $4,430	  
EMOD	   $12,319	   $12,590	   $12,867	   $4,548	   $4,801	   $5,071	   $1,436	   $1,692	   $1,989	  
BBH	   $4,434	   $4,561	   $4,690	   $1,770	   $1,894	   $2,027	   $689	   $795	   $922	  
PopART	   $4,869	   $4,920	   $4,968	   $2,166	   $2,334	   $2,506	   $660	   $822	   $1,015	  
Synthesis	   $8,106	   $8,223	   $8,341	   $3,971	   $4,131	   $4,300	   $1,925	   $2,133	   $2,367	  
Menzies	   $19,656	   $20,120	   $20,589	   $4,540	   $4,910	   $5,310	   $918	   $1,132	   $1,394	  
CD4	  ≤350,	  
expanded	  vs.	  CD4	  
≤350,	  status	  quo	  
Goals	   $4,123	   $4,175	   $4,226	   $2,596	   $2,685	   $2,776	   $1,502	   $1,627	   $1,767	  
STDSIM	   $6,994	   $7,127	   $7,263	   $4,326	   $4,492	   $4,666	   $2,475	   $2,701	   $2,954	  
EMOD	   $3,703	   $3,749	   $3,795	   $2,390	   $2,477	   $2,566	   $1,379	   $1,505	   $1,645	  
BBH	   $2,433	   $2,476	   $2,519	   $1,617	   $1,675	   $1,736	   $1,110	   $1,187	   $1,272	  
PopART	   $3,706	   $3,764	   $3,823	   $2,518	   $2,604	   $2,692	   $1,623	   $1,750	   $1,890	  
Synthesis	   $2,912	   $2,978	   $3,044	   $1,844	   $1,933	   $2,025	   $1,291	   $1,398	   $1,518	  
Menzies	   $2,688	   $2,722	   $2,757	   $1,531	   $1,594	   $1,659	   $588	   $686	   $796	  
CD4	  ≤500	  
expanded	  vs.	  CD4	  
≤350	  status	  quo	  
Goals	   $4,167	   $4,227	   $4,287	   $2,388	   $2,486	   $2,587	   $1,247	   $1,371	   $1,512	  
STDSIM	   $6,529	   $6,648	   $6,769	   $3,973	   $4,136	   $4,305	   $2,078	   $2,303	   $2,556	  
EMOD	   $4,462	   $4,527	   $4,592	   $2,667	   $2,784	   $2,906	   $1,357	   $1,521	   $1,705	  
BBH	   $2,791	   $2,848	   $2,905	   $1,681	   $1,755	   $1,833	   $1,012	   $1,104	   $1,208	  
PopART	   $3,757	   $3,819	   $3,880	   $2,281	   $2,380	   $2,483	   $1,251	   $1,382	   $1,528	  
Synthesis	   $3,218	   $3,287	   $3,356	   $2,037	   $2,134	   $2,234	   $1,375	   $1,497	   $1,632	  
All	  HIV+	  
expanded	  vs.	  CD4	  
≤350	  status	  quo	  
Goals	   $4,775	   $4,859	   $4,942	   $2,438	   $2,560	   $2,687	   $1,110	   $1,248	   $1,407	  
STDSIM	   $9,451	   $9,624	   $9,800	   $5,511	   $5,755	   $6,010	   $2,627	   $2,961	   $3,335	  
EMOD	   $4,560	   $4,629	   $4,698	   $2,693	   $2,816	   $2,943	   $1,339	   $1,508	   $1,698	  
BBH	   $2,905	   $2,968	   $3,031	   $1,688	   $1,768	   $1,852	   $942	   $1,040	   $1,152	  
PopART	   $4,127	   $4,197	   $4,265	   $2,253	   $2,378	   $2,507	   $1,000	   $1,153	   $1,327	  
Synthesis	   $3,597	   $3,677	   $3,757	   $2,185	   $2,297	   $2,413	   $1,370	   $1,514	   $1,674	  
Menzies	   $6,780	   $6,875	   $6,969	   $2,703	   $2,874	   $3,053	   $696	   $861	   $1,054	  
All	  HIV+,	  status	  
quo	  vs.	  CD4	  ≤500,	  
status	  quo	  
Goals	   $7,729	   $7,987	   $8,250	   $2,034	   $2,223	   $2,427	   $432	   $558	   $713	  
STDSIM	   $75,694	   $77,895	   $80,145	   $27,854	   $29,729	   $31,749	   $7,700	   $9,088	   $10,772	  
EMOD	   $17,772	   $17,824	   $17,876	   $6,875	   $7,225	   $7,591	   $2,092	   $2,498	   $2,964	  
BBH	   $5,604	   $5,770	   $5,939	   $2,033	   $2,193	   $2,365	   $600	   $717	   $860	  
PopART	   $6,190	   $6,229	   $6,265	   $2,802	   $3,033	   $3,264	   $629	   $870	   $1,155	  
Synthesis	   $18,756	   $19,110	   $19,468	   $6,234	   $6,568	   $6,927	   $2,516	   $2,856	   $3,249	  
CD4	  ≤500,	  
expanded	  vs.	  CD4	  
≤350,	  expanded	  
Goals	   $4,504	   $4,635	   $4,766	   $1,357	   $1,477	   $1,607	   $309	   $401	   $512	  
STDSIM	   $4,818	   $4,899	   $4,980	   $2,455	   $2,619	   $2,786	   $585	   $788	   $1,022	  
EMOD	   $21,838	   $22,397	   $22,956	   $8,315	   $9,111	   $9,944	   $981	   $1,814	   $2,791	  
BBH	   $4,928	   $5,080	   $5,233	   $1,941	   $2,086	   $2,243	   $750	   $872	   $1,017	  
PopART	   $3,997	   $4,072	   $4,144	   $1,440	   $1,576	   $1,718	   $410	   $509	   $632	  
Synthesis	   $10,421	   $10,518	   $10,614	   $5,721	   $6,010	   $6,305	   $2,445	   $2,815	   $3,235	  
All	  HIV+,	  
expanded	  vs.	  CD4	  
≤350,	  expanded	  
Goals	   $7,648	   $7,901	   $8,158	   $2,017	   $2,220	   $2,439	   $378	   $516	   $686	  
STDSIM	   $17,058	   $17,313	   $17,570	   $9,472	   $9,960	   $10,460	   $3,032	   $3,666	   $4,397	  
EMOD	   $22,832	   $23,495	   $24,159	   $8,260	   $9,103	   $9,990	   $720	   $1,561	   $2,555	  
BBH	   $4,822	   $4,976	   $5,133	   $1,889	   $2,037	   $2,197	   $641	   $764	   $912	  
PopART	   $5,232	   $5,313	   $5,390	   $1,663	   $1,873	   $2,091	   $127	   $277	   $463	  
Synthesis	   $22,301	   $22,824	   $23,340	   $6,833	   $7,423	   $8,057	   $1,974	   $2,461	   $3,043	  
Menzies	   $20,421	   $20,867	   $21,316	   $4,582	   $4,986	   $5,421	   $794	   $1,024	   $1,308	  
All	  HIV+,	  
expanded	  vs.	  CD4	  
≤500	  expanded	  
Goals	   $11,900	   $12,340	   $12,790	   $2,780	   $3,083	   $3,412	   $449	   $636	   $867	  
STDSIM	   $82,898	   $84,726	   $86,580	   $34,080	   $36,270	   $38,586	   $8,876	   $10,809	   $13,135	  
EMOD	   $36,267	   $38,699	   $41,267	   $7,774	   $9,030	   $10,419	   A	   A	   $733	  
BBH	   $4,594	   $4,755	   $4,918	   $1,767	   $1,923	   $2,091	   $422	   $544	   $694	  
PopART	   $6,793	   $6,857	   $6,915	   $2,037	   $2,364	   $2,693	   A	   A	   $189	  
Synthesis	   B	   B	   B	   $9,622	   $11,241	   $13,208	   $1,266	   $1,901	   $2,720	  
‘A’	  indicates	  the	  policy	  listed	  first	  dominates	  the	  policy	  listed	  second	  (i.e.	  lower	  cost,	  greater	  health	  benefits).	  ‘B’	  
indicates	  the	  policy	  listed	  second	  dominates	  the	  policy	  listed	  first.	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Table	  S8:	  Cost	  per	  DALY	  averted	  (2012	  US$)	  comparing	  selected	  strategies	  in	  models	  for	  
Zambia	  
	  	   	  	   5	  years	   10	  years	   20	  years	  
	  	   	  	   0%	  disc.	   3%	  disc.	   6%	  disc	   0%	  disc.	   3%	  disc.	   6%	  disc	   0%	  disc.	   3%	  disc.	   6%	  disc	  
CD4	  ≤500,	  status	  
quo	  vs.	  CD4	  ≤350,	  
status	  quo	  
Goals	   $1,253	   $1,296	   $1,339	   $230	   $290	   $354	   A	   A	   A	  
EMOD	   $5,448	   $5,567	   $5,687	   $2,266	   $2,406	   $2,555	   $595	   $749	   $926	  
Macha	   $1,270	   $1,303	   $1,336	   $446	   $477	   $510	   $105	   $131	   $163	  
PopART	   $2,301	   $2,349	   $2,397	   $936	   $1,002	   $1,071	   $311	   $364	   $429	  
All	  HIV+,	  status	  
quo	  vs.	  CD4	  ≤350,	  
status	  quo	  
Goals	   $2,612	   $2,690	   $2,768	   $706	   $802	   $903	   A	   A	   $77	  
EMOD	   $6,530	   $6,681	   $6,835	   $2,535	   $2,700	   $2,876	   $620	   $790	   $988	  
Macha	   $1,229	   $1,262	   $1,295	   $433	   $464	   $497	   $101	   $128	   $159	  
PopART	   $3,653	   $3,751	   $3,849	   $1,134	   $1,247	   $1,368	   $160	   $237	   $333	  
CD4	  ≤350,	  
expanded	  vs.	  CD4	  
≤350,	  status	  quo	  
Goals	   $5,227	   $5,282	   $5,336	   $3,687	   $3,788	   $3,891	   $2,333	   $2,493	   $2,670	  
EMOD	   $4,383	   $4,436	   $4,489	   $2,834	   $2,927	   $3,024	   $1,708	   $1,836	   $1,980	  
Macha	   $2,574	   $2,601	   $2,628	   $1,757	   $1,809	   $1,862	   $1,114	   $1,193	   $1,281	  
PopART	   $3,043	   $3,089	   $3,136	   $2,106	   $2,173	   $2,243	   $1,336	   $1,436	   $1,546	  
CD4	  ≤500	  
expanded	  vs.	  CD4	  
≤350	  status	  quo	  
Goals	   $4,161	   $4,221	   $4,280	   $2,517	   $2,614	   $2,715	   $1,365	   $1,495	   $1,643	  
EMOD	   $4,852	   $4,925	   $4,997	   $2,778	   $2,900	   $3,026	   $1,337	   $1,496	   $1,676	  
Macha	   $2,043	   $2,079	   $2,114	   $1,021	   $1,072	   $1,125	   $433	   $489	   $555	  
PopART	   $3,038	   $3,098	   $3,159	   $1,606	   $1,690	   $1,778	   $705	   $796	   $902	  
All	  HIV+,	  
expanded	  vs.	  CD4	  
≤350,	  status	  quo	  
Goals	   $4,240	   $4,317	   $4,395	   $2,165	   $2,279	   $2,398	   $942	   $1,073	   $1,224	  
EMOD	   $4,953	   $5,031	   $5,109	   $2,764	   $2,892	   $3,024	   $1,273	   $1,437	   $1,622	  
Macha	   $1,970	   $2,006	   $2,041	   $970	   $1,020	   $1,072	   $406	   $460	   $523	  
PopART	   $3,467	   $3,554	   $3,642	   $1,404	   $1,516	   $1,635	   $331	   $431	   $551	  
All	  HIV+,	  status	  
quo	  vs.	  CD4	  ≤500,	  
status	  quo	  
Goals	   $4,534	   $4,678	   $4,823	   $1,160	   $1,298	   $1,447	   A	   $57	   $186	  
EMOD	   $39,639	   $42,346	   $45,317	   $5,139	   $5,618	   $6,149	   $788	   $1,080	   $1,436	  
Macha	   $979	   $1,012	   $1,046	   $336	   $367	   $401	   $71	   $96	   $127	  
PopART	   $6,260	   $6,474	   $6,692	   $1,449	   $1,642	   $1,849	   A	   $69	   $205	  
CD4	  ≤500,	  
expanded	  vs.	  CD4	  
≤350,	  expanded	  
Goals	   $1,623	   $1,674	   $1,726	   $373	   $435	   $500	   A	   A	   A	  
EMOD	   $7,415	   $7,610	   $7,806	   $2,519	   $2,771	   $3,037	   A	   $160	   $455	  
Macha	   $1,317	   $1,352	   $1,387	   $426	   $460	   $496	   $80	   $108	   $141	  
PopART	   $3,025	   $3,121	   $3,219	   $844	   $933	   $1,029	   $143	   $197	   $266	  
All	  HIV+,	  
expanded	  vs.	  CD4	  
≤350,	  expanded	  
Goals	   $2,921	   $3,016	   $3,113	   $731	   $832	   $939	   A	   A	   $51	  
EMOD	   $7,830	   $8,058	   $8,288	   $2,472	   $2,741	   $3,025	   A	   $56	   $357	  
Macha	   $1,263	   $1,297	   $1,333	   $408	   $442	   $477	   $75	   $102	   $135	  
PopART	   $4,123	   $4,281	   $4,442	   $768	   $905	   $1,054	   A	   A	   A	  
All	  HIV+,	  
expanded	  vs.	  CD4	  
≤500	  expanded	  
Goals	   $4,580	   $4,739	   $4,899	   $1,111	   $1,256	   $1,412	   A	   $14	   $153	  
EMOD	   $12,796	   $13,581	   $14,418	   $2,103	   $2,495	   $2,926	   A	   A	   A	  
Macha	   $941	   $976	   $1,013	   $274	   $307	   $342	   $30	   $55	   $87	  
PopART	   $5,723	   $5,973	   $6,228	   $658	   $865	   $1,091	   A	   A	   A	  
‘A’	  indicates	  the	  policy	  listed	  first	  dominates	  the	  policy	  listed	  second	  (i.e.	  lower	  cost,	  greater	  health	  benefits).	  ‘B’	  indicates	  the	  
policy	  listed	  second	  dominates	  the	  policy	  listed	  first.	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Table	  S9:	  Cost	  per	  DALY	  averted	  (2012	  US$)	  compared	  to	  baseline	  strategy	  (CD4	  ≤350	  cells/µL	  
eligibility,	  status	  quo	  access)	  in	  models	  for	  India	  
Strategya	   5	  years	   10	  years	   20	  years	  
	  	   0%	  disc.	   3%	  disc.	   6%	  disc	   0%	  disc.	   3%	  disc.	   6%	  disc	   0%	  disc.	   3%	  disc.	   6%	  disc	  
Mishra	  (Belgaum)	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
all	  HIV+,	  status	  quo	   $1,195	   $1,231	   $1,267	   $437	   $466	   $497	   $173	   $198	   $228	  
FSW	  elig.,	  status	  quo	   $831	   $857	   $884	   $252	   $271	   $291	   $71	   $85	   $102	  
CD4	  ≤350,	  exp.	  FSW	   $2,121	   $2,153	   $2,186	   $886	   $929	   $976	   $348	   $390	   $440	  
FSW	  elig.,	  exp.	  FSW	   $1,468	   $1,501	   $1,534	   $508	   $539	   $573	   $176	   $202	   $232	  
all	  HIV+,	  exp.	  FSW	   $1,381	   $1,417	   $1,455	   $514	   $547	   $581	   $206	   $235	   $269	  
CD4	  ≤350,	  unif.	  exp.	   $13,983	   $14,155	   $14,327	   $7,892	   $8,169	   $8,458	   $5,062	   $5,396	   $5,773	  
all	  HIV+,	  unif.	  exp.	   $11,602	   $11,764	   $11,927	   $6,012	   $6,249	   $6,497	   $3,660	   $3,927	   $4,230	  
FSW	  elig.,	  unif.	  exp	   $13,360	   $13,528	   $13,697	   $7,377	   $7,645	   $7,923	   $4,605	   $4,925	   $5,285	  
Mishra,	  no	  FSW	  intervention	   	  	  
	  
	  	  




all	  HIV+,	  status	  quo	   $1,282	   $1,316	   $1,350	   $512	   $538	   $566	   $219	   $241	   $266	  
FSW	  elig.,	  status	  quo	   $655	   $673	   $690	   $213	   $225	   $239	   $65	   $73	   $83	  
CD4	  ≤350,	  exp.	  FSW	   $1,352	   $1,376	   $1,401	   $439	   $462	   $488	   $124	   $141	   $161	  
FSW	  elig.,	  exp.	  FSW	   $1,273	   $1,298	   $1,323	   $368	   $389	   $411	   $98	   $112	   $129	  
all	  HIV+,	  exp.	  FSW	   $1,299	   $1,325	   $1,352	   $386	   $408	   $431	   $106	   $121	   $139	  
CD4	  ≤350,	  unif.	  exp.	   $7,296	   $7,403	   $7,511	   $3,475	   $3,624	   $3,781	   $1,631	   $1,794	   $1,982	  
all	  HIV+,	  unif.	  exp.	   $7,065	   $7,171	   $7,278	   $3,253	   $3,397	   $3,549	   $1,470	   $1,623	   $1,800	  
FSW	  elig.,	  unif.	  exp	   $6,543	   $6,649	   $6,755	   $2,834	   $2,968	   $3,109	   $1,274	   $1,409	   $1,565	  
Pruddell	  (Bangalore)	   	  	  
	  
	  	  




FSW	  elig.,	  status	  quo	   $1,206	   $1,244	   $1,283	   $249	   $275	   $303	   $11	   $24	   $40	  
MSM	  elig.,	  status	  quo	   $2,740	   $2,820	   $2,903	   $690	   $752	   $821	   $95	   $128	   $169	  
FSW	  &	  MSM	  elig,	  status	  quo	   $2,179	   $2,246	   $2,314	   $513	   $562	   $614	   $61	   $85	   $116	  
all	  HIV+,	  status	  quo	   $2,573	   $2,650	   $2,728	   $649	   $708	   $772	   $100	   $131	   $170	  
FSW	  elig.,	  exp.	  FSW	   $1,173	   $1,199	   $1,225	   $394	   $420	   $447	   $87	   $106	   $129	  
MSM	  elig.,	  exp.	  MSM	   $1,856	   $1,894	   $1,933	   $895	   $945	   $997	   $324	   $377	   $438	  
CD4	  ≤350,	  exp.	  FSW	  &	  MSM	   $1,700	   $1,733	   $1,766	   $878	   $920	   $964	   $350	   $398	   $455	  
FSW	  &	  MSM	  elig,	  exp.	  FSW	  &	  
MSM	  
$1,759	   $1,796	   $1,834	   $795	   $841	   $890	   $264	   $310	   $364	  
IDU-­‐Manipur	  (Churachandpur)	   	  	  
	  
	  	  




PWID	  elig.,	  status	  quo	   $2,787	   $2,848	   $2,910	   $657	   $710	   $766	   $73	   $107	   $149	  
PWID	  &	  ex-­‐PWID	  elig,	  status	  quo	   $3,535	   $3,615	   $3,695	   $882	   $949	   $1,020	   $152	   $197	   $250	  
CD4	  ≤350,	  exp.	  PWID	   $1,572	   $1,591	   $1,610	   $871	   $911	   $951	   $427	   $487	   $553	  
PWID	  elig.,	  exp.	  PWID	   $1,884	   $1,916	   $1,948	   $655	   $706	   $758	   $98	   $143	   $196	  
CD4	  ≤350,	  exp.	  PWID	  &	  ex-­‐PWID	   $1,691	   $1,720	   $1,748	   $1,003	   $1,046	   $1,091	   $666	   $723	   $785	  
PWID	  elig,	  exp	  PWID	  &	  ex-­‐PWID	   $1,848	   $1,882	   $1,916	   $825	   $877	   $932	   $261	   $319	   $386	  
PWID	  &	  ex-­‐PWID	  elig,	  exp.	  PWID	  
&	  ex-­‐PWID	  
$1,981	   $2,017	   $2,054	   $863	   $920	   $978	   $270	   $330	   $401	  
a	  Strategy	  represented	  as	  <	  eligibility,	  access	  >.	  For	  example	  ‘CD4	  ≤350,	  exp.	  FSW’	  indicates	  all	  adults	  with	  CD4	  ≤350	  
cells/µL	  are	  eligible	  and	  prioritised	  expanded	  access	  to	  FSW.	  ‘unif.	  exp.’	  indicates	  uniformly	  expanded	  access	  to	  the	  general	  
population.	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Table	  S10:	  Cost	  per	  DALY	  averted	  (2012	  US$)	  compared	  to	  baseline	  strategy	  (CD4	  ≤350	  cells/µL	  
eligibility,	  status	  quo	  access)	  in	  model	  for	  Vietnam	  
Strategya	   5	  years	   10	  years	   20	  years	  
	  	   0%	  disc.	   3%	  disc.	   6%	  disc	   0%	  disc.	   3%	  disc.	   6%	  disc	   0%	  disc.	   3%	  disc.	   6%	  disc	  
Prevtool	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
FSW	  elig.,	  status	  quo	   $1,664	   $1,702	   $1,740	   $531	   $557	   $585	   $143	   $161	   $182	  
MSM	  elig.,	  status	  quo	   $2,060	   $2,105	   $2,151	   $749	   $783	   $818	   $254	   $280	   $311	  
PWID	  elig.,	  status	  quo	   $2,030	   $2,076	   $2,122	   $743	   $777	   $814	   $247	   $274	   $306	  
CD4	  ≤500	  elig,	  status	  quo	   $1,241	   $1,265	   $1,290	   $578	   $598	   $620	   $270	   $290	   $313	  
All	  HIV+	  elig,	  status	  quo	   $2,055	   $2,100	   $2,146	   $758	   $791	   $827	   $263	   $289	   $320	  
FSW	  elig.,	  exp.	  FSW	   $18,779	   $19,420	   $20,082	   $5,004	   $5,362	   $5,754	   $1,270	   $1,465	   $1,705	  
MSM	  elig,	  exp.	  MSM	   $11,604	   $11,981	   $12,369	   $3,623	   $3,863	   $4,124	   $1,187	   $1,354	   $1,555	  
PWID	  elig.,	  exp.	  PWID	   $10,529	   $10,864	   $11,210	   $3,430	   $3,652	   $3,893	   $1,153	   $1,311	   $1,502	  
CD4	  ≤350,	  exp.	  FSW,	  MSM,	  PWID	   $16,614	   $17,131	   $17,663	   $6,190	   $6,568	   $6,977	   $2,392	   $2,692	   $3,050	  
CD4	  ≤500,	  exp.	  FSW,	  MSM,	  PWID	   $12,708	   $13,114	   $13,533	   $4,415	   $4,692	   $4,994	   $1,631	   $1,839	   $2,090	  
All	  HIV+,	  exp.	  FSW,	  MSM,	  PWID	   $11,664	   $12,042	   $12,432	   $3,659	   $3,901	   $4,164	   $1,194	   $1,361	   $1,563	  
CD4	  ≤350,	  uniformly	  expanded	   $87,266	   $90,024	   $92,861	   $33,608	   $35,635	   $37,833	   $14,277	   $15,932	   $17,910	  
CD4	  ≤500,	  uniformly	  expanded	   $69,338	   $71,610	   $73,951	   $24,812	   $26,372	   $28,068	   $10,097	   $11,303	   $12,750	  
All	  HIV+,	  uniformly	  expanded	   $63,176	   $65,296	   $67,481	   $20,786	   $22,153	   $23,644	   $7,847	   $8,835	   $10,028	  
a	  Strategy	  represented	  as	  <	  eligibility,	  access	  >.	  For	  example	  ‘CD4	  ≤350,	  exp.	  FSW’	  indicates	  all	  adults	  with	  CD4	  ≤350	  
cells/µL	  are	  eligible	  and	  prioritised	  expanded	  access	  to	  FSW.	  ‘unif.	  exp.’	  indicates	  uniformly	  expanded	  access	  to	  the	  general	  
population.	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